APAC IPOs & Placements, Aequitas Research

Akshat Shah

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Ringpai Veterinary Hospital Management / Equity Capital Markets

Ringpai Veterinary Hospital Management (RPVH HK)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/ringpai-veterinary-hospital-management-holdings" target="_blank" data-smartkarma-citation="entities:46189:1" rel="noopener">Ringpai Veterinary Hospital Management (RPVH HK)</a> plans to raise around US$500m in its upcoming Hong Kong IPO.</li>
<li>Ringpai Veterinary Hospital (RVH) operates a leading network of pet hospitals across China, delivering high-quality veterinary care through clinical expertise, professional standards, and compassionate service across the full pet lifecycle.</li>
<li>In this note, we look at the positive aspects of the company’s past performance.</li>
</ul>



Ringpai Veterinary Hospital Management (RPVH HK) plans to raise around US$500m in its upcoming Hong Kong IPO.
Ringpai Veterinary Hospital (RVH) operates a leading network of pet hospitals across China, delivering high-quality veterinary care through clinical expertise, professional standards, and compassionate service across the full pet lifecycle.
In this note, we look at the positive aspects of the company’s past performance.


Aequitas: Ringpai Vet Hospital Pre-IPO - The Positives - Scaling China’s Veterinary Care Platform

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>IDEXX Laboratories, Inc. reported robust financial results for the second quarter of 2025, underpinned by strong execution, particularly in their Companion Animal Group (CAG) business.</li><li>The company's revenue increased 11% as reported and 9% organically.</li><li>Growth was driven notably by advancements in their CAG Diagnostic Recurring Revenues, which benefited from significant CAG instrument sales and a strong international performance.</li></ul>

IDEXX Laboratories, Inc. reported robust financial results for the second quarter of 2025, underpinned by strong execution, particularly in their Companion Animal Group (CAG) business.The company's revenue increased 11% as reported and 9% organically.Growth was driven notably by advancements in their CAG Diagnostic Recurring Revenues, which benefited from significant CAG instrument sales and a strong international performance.

<ul><li>IDEXX Laboratories reported its first-quarter 2025 financial results, revealing a mixed performance with notable areas of strength as well as challenges.</li><li>Overall, IDEXX achieved a 5% organic revenue growth, a figure backed by a 4.5% increase in CAG Diagnostics recurring revenues despite facing a 1.5% headwind from fewer equivalent days.</li><li>The company's veterinary software and diagnostic imaging revenues were particularly strong, showing a 9% organic gain, highlighting robust demand in this segment.</li></ul>

IDEXX Laboratories reported its first-quarter 2025 financial results, revealing a mixed performance with notable areas of strength as well as challenges.Overall, IDEXX achieved a 5% organic revenue growth, a figure backed by a 4.5% increase in CAG Diagnostics recurring revenues despite facing a 1.5% headwind from fewer equivalent days.The company's veterinary software and diagnostic imaging revenues were particularly strong, showing a 9% organic gain, highlighting robust demand in this segment.

IDEXX Laboratories Is Defying Global Economic Shocks—How Is It Thriving Amid Tariff Turbulence & Market Volatility?

Independent in-depth research from Finimize, Finimize

Finimize Research

Independent in-depth research from Finimize

Finimize

Finimize is the #1 information platform for modern investors. We empower people to become smarter investors with bitesize insights from world-class analysts. 1 million+ strong community, 250 partners.

<ul>
<li>IDEXX Laboratories,  a $35 billion company, is a global leader in veterinary diagnostics, selling and developing the tools that help vets diagnose and treat animals.</li>
<li>IDEXX operates a highly recurring, subscription-like business model, particularly in its Companion Animal Group (CAG), which accounts for over 90% of its revenue.</li>
<li>IDEXX is a cash-generating, high-return compounder at the center of a booming industry and stock looks undervalued right now.</li>
</ul>


IDEXX Laboratories,  a $35 billion company, is a global leader in veterinary diagnostics, selling and developing the tools that help vets diagnose and treat animals.
IDEXX operates a highly recurring, subscription-like business model, particularly in its Companion Animal Group (CAG), which accounts for over 90% of its revenue.
IDEXX is a cash-generating, high-return compounder at the center of a booming industry and stock looks undervalued right now.


IDEXX: Pet Healthcare Could Be An Investor's Best Friend

<ul><li>IDEXX Laboratories, a global leader in veterinary diagnostics, software, and water quality products, closed out 2024 with a solid performance, surpassing expectations and setting a strong foundation for 2025.</li><li>The company reported a 6% organic revenue increase in Q4 2024, driven by a 7% rise in its core Companion Animal Group (CAG) Diagnostic recurring revenues.</li><li>Operating profits grew 7% as reported, and 8% on a comparable basis, supported by favorable gross margin gains.</li></ul>

IDEXX Laboratories, a global leader in veterinary diagnostics, software, and water quality products, closed out 2024 with a solid performance, surpassing expectations and setting a strong foundation for 2025.The company reported a 6% organic revenue increase in Q4 2024, driven by a 7% rise in its core Companion Animal Group (CAG) Diagnostic recurring revenues.Operating profits grew 7% as reported, and 8% on a comparable basis, supported by favorable gross margin gains.

IDEXX Laboratories: Executing International Expansion To Capitalize On Its Competitive Edge Across Global Veterinary Markets!

United States

IDEXX Laboratories, Inc. provides diagnostic, detection, and information systems for veterinary, food, and water testing applications. The Company also operates an international network of veterinary reference laboratories. IDEXX offers its products to customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

IDEXX Laboratories (IDXX US)

Aequitas: Ringpai Vet Hospital Pre-IPO - The Positives - Scaling China’s Veterinary Care Platform

Ringpai Veterinary Hospital (RVH) plans to raise around US$500m in its upcoming Hong Kong IPO. In this note, we look at the positive aspects of the...

Akshat Shah

IDEXX Laboratories Hits 10

IDEXX Laboratories, Inc. reported robust financial results for the second quarter of 2025, underpinned by strong execution, particularly in their...

Baptista Research

IDEXX Laboratories Is Defying Global Economic Shocks—How Is It Thriving Amid Tariff Turbulence & Market Volatility?

IDEXX Laboratories reported its first-quarter 2025 financial results, revealing a mixed performance with notable areas of strength as well as...

Baptista Research

IDEXX: Pet Healthcare Could Be An Investor's Best Friend

IDEXX Laboratories is a global leader in veterinary diagnostics, and operates a highly recurring, subscription-like business model, with EBITDA...

Finimize Research

IDEXX Laboratories: Executing International Expansion To Capitalize On Its Competitive Edge Across Global Veterinary Markets!

IDEXX Laboratories, a global leader in veterinary diagnostics, software, and water quality products, closed out 2024 with a solid performance,...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)